Machineries regulating the activity of the small GTPase Arf6 in cancer cells are potential targets for developing innovative anti-cancer drugs

详细信息    查看全文

• 作者：Yohei Yamauchi ; Yuki Miura ; Yasunori Kanaho ; ^{ykanaho@md.tsukuba.ac.jp}
• 关键词：Arf6 ; GEF ; GAP ; Invasion ; Metastasis ; Tumor angiogenesis ; Tumor growth ; Anti-cancer drugs
• 刊名：Advances in Biological Regulation
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：63
• 期：Complete
• 页码：115-121
• 全文大小：816 K
• 卷排序：63

文摘

The Small GTPase ADP-ribosylation factor 6 (Arf6) functions as the molecular switch in cellular signaling pathways by cycling between GDP-bound inactive and GTP-bound active form, which is precisely regulated by two regulators, guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Numerous studies have shown that these machineries play critical roles in tumor angiogenesis/growth and cancer cell invasion/metastasis through regulating the cycling of Arf6. Here, we summarize accumulating knowledge for involvement of Arf6 GEFs/GAPs and small molecule inhibitors of Arf6 signaling/cycling in cancer progression, and discuss possible strategies for developing innovative anti-cancer drugs targeting Arf6 signaling/cycling.